DAIC

FEBRUARY 6, 2024

The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

DAIC

APRIL 18, 2024

Two articles and an accompanying editorial in Heart Rhythm , the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society , and the Pediatric & Congenital Electrophysiology Society , published by Elsevier , address the controversy and recommend shortening the blanking period.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

DAIC

JANUARY 31, 2024

A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,

Ablation 111

Ablation Atrial Fibrillation Anatomy Pulmonary 111

DAIC

DECEMBER 29, 2023

Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent. Patients are often treated with AADs as frontline therapy for heart rhythm maintenance, though some can experience adverse effects and limited efficacy.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

DAIC

MAY 18, 2024

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

Heart Rhythm 105

Heart Rhythm Atrial Fibrillation Ablation Quality of Life 105

DAIC

MARCH 27, 2025

The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1% Volt PFA System PFA works differently from traditional ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms.

Ablation 52

Ablation AFIB Atrial Fibrillation Electrophysiology 52

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105